Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 18, Issue -, Pages 17-24
Publisher
Wiley
Online
2016-10-13
DOI
10.1111/dom.12753
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials
- (2016) Henry Ginsberg et al. DIABETES OBESITY & METABOLISM
- Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes
- (2016) K. Cusi et al. DIABETES OBESITY & METABOLISM
- Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4
- (2016) T. Blevins et al. DIABETES OBESITY & METABOLISM
- Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial
- (2016) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial
- (2016) G. Grunberger et al. DIABETES OBESITY & METABOLISM
- Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
- (2016) R. M. Bergenstal et al. DIABETES OBESITY & METABOLISM
- A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1
- (2016) S. Garg et al. DIABETES OBESITY & METABOLISM
- Insulin Delivery Into the Peripheral Circulation: A Key Contributor to Hypoglycemia in Type 1 Diabetes
- (2015) Justin M. Gregory et al. DIABETES
- Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5
- (2015) John B. Buse et al. DIABETES CARE
- Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects
- (2014) Vikram P. Sinha et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism
- (2013) M. C. Moore et al. DIABETES
- Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM
- (2013) S. J. Jacober et al. DIABETES OBESITY & METABOLISM
- Hepatoselectivity and the evolution of insulin
- (2013) R. Herring et al. DIABETES OBESITY & METABOLISM
- Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study
- (2012) J. Rosenstock et al. DIABETES CARE
- A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes
- (2012) R. M. Bergenstal et al. DIABETES CARE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now